AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26709060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and low-dose simvastatin
Number of subjects: 0
Study 26709060 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25426862 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance
Number of subjects: 2043
Study 25426862 — intervention group
Group type: COMPARATOR
Intervention: LVEF
Number of subjects: 2043
Study 25426862 — intervention group
Group type: COMPARATOR
Intervention: NYHA functional class
Number of subjects: 2043
Study 25426862 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE <24
Number of subjects: 2043
Study 23597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy group (placebo cream applied)
Number of subjects: 58
Study 23597333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placebo cream applied)
Number of subjects: 58
Study 20578644 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acupuncture (13 patients)
Number of subjects: 31
Study 20578644 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (16 patients)
Number of subjects: 31
Study 18394150 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training in diagnostic coding
Number of subjects: 84
Study 18394150 — intervention group
Group type: COMPARATOR
Intervention: General educational program
Number of subjects: 84
Study 16672069 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ-An Satisfaction subscale
Number of subjects: 312
Study 16672069 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ-An Treatment burden subscale
Number of subjects: 312
Study 16672069 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ-An Overall satisfaction subscale
Number of subjects: 312
Study 16672069 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 312
Study 16672069 — intervention group
Group type: EXPERIMENTAL
Intervention: Construct validity
Number of subjects: 312
Study 14670699 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-comparison method for judging relative complexity of band patterns
Number of subjects: 0
Study 14670699 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetry properties of band patterns
Number of subjects: 0
Study 11008329 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-75 mg/day)
Number of subjects: 52
Study 11008329 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (5-20 mg/day)
Number of subjects: 52
Study 11008329 — intervention group
Group type: COMPARATOR
Intervention: No ACE-inhibitor therapy (Control group)
Number of subjects: 52
Study 11008329 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril or Fosinopril
Number of subjects: 52
Study 9103725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (16 weekly sessions)
Number of subjects: 76
Study 9103725 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (6-12 weeks)
Number of subjects: 76
Study 8095251 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg (once a day)
Number of subjects: 40
Study 8095251 — intervention group
Group type: COMPARATOR
Intervention: Captopril 20 mg (twice a day)
Number of subjects: 40
Study 3527720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay m 1099 (100 mg before breakfast and dinner)
Number of subjects: 15
Study 3527720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29763657 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based care model (daily BP measurement using smartphone and wireless BP monitor, bi-weekly medication adjustments)
Number of subjects: 50
Study 29763657 — intervention group
Group type: COMPARATOR
Intervention: Usual care (digital BP monitor provided)
Number of subjects: 50
Study 26849087 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% trichloroacetic acid (TCA)
Number of subjects: 0
Study 26849087 — intervention group
Group type: EXPERIMENTAL
Intervention: 88% phenol
Number of subjects: 0
Study 26849087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCA and phenol
Number of subjects: 0
Study 25277997 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 298
Study 25277997 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 298
Study 22801130 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 47
Study 22801130 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:100,000
Number of subjects: 47
Study 22801130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure rate quotient
Number of subjects: 47
Study 20070849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention for panic symptoms
Number of subjects: 217
Study 20070849 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 217
Study 18564802 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 100
Study 18564802 — intervention group
Group type: COMPARATOR
Intervention: Classic LMA
Number of subjects: 100
Study 18564802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 100
Study 16372827 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 5mg and 50mg (single intravenous doses)
Number of subjects: 48
Study 16372827 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 15mg and 150mg (single intravenous doses)
Number of subjects: 48
Study 16372827 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50mg (single intravenous, subcutaneous and intramuscular doses)
Number of subjects: 48
Study 16372827 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50mg (repeat subcutaneous administration of six doses every 48 hours)
Number of subjects: 48
Study 16372827 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 100mg and 150mg (repeat subcutaneous administration of six doses over 2 weeks)
Number of subjects: 48
Study 11235499 — intervention group
Group type: EXPERIMENTAL
Intervention: New nonprescription medication
Number of subjects: 19
Study 11235499 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 19
Study 9703836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 250 mg/day with Limethason 1 A (4.0 mg of dexamethasone palmitate) in Group B
Number of subjects: 24
Study 9703836 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 250 mg/day in Group A
Number of subjects: 24
Study 7816530 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics treatment in infants with congenital heart disease
Number of subjects: 7
Study 7816530 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 7
Study 3050936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg single dose
Number of subjects: 41
Study 3050936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.d. chronic dosing
Number of subjects: 41
Study 3050936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg b.d. chronic dosing
Number of subjects: 41
Study 3050936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin mean dose 73 mg/day for 7 weeks
Number of subjects: 41
Study 3050936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin mean dose 167 mg/day
Number of subjects: 41
Study 1540479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 50
Study 1540479 — intervention group
Group type: COMPARATOR
Intervention: Simple placebo
Number of subjects: 50
Study 1540479 — intervention group
Group type: COMPARATOR
Intervention: Placebo with implied therapeutic action
Number of subjects: 50
Study 351982 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 748
Study 351982 — intervention group
Group type: COMPARATOR
Intervention: Selective gastric vagotomy (SGV) + drainage (D)
Number of subjects: 748
Study 351982 — intervention group
Group type: COMPARATOR
Intervention: Selective gastric vagotomy (SGV) + antrectomy (A)
Number of subjects: 748
Study 351982 — intervention group
Group type: COMPARATOR
Intervention: PCV + drainage (D)
Number of subjects: 748
Study 29912724 — intervention group
Group type: EXPERIMENTAL
Intervention: LPs performed by right-handed physicians with patients in the left lateral recumbent position (LRP)
Number of subjects: 7200
Study 29912724 — intervention group
Group type: EXPERIMENTAL
Intervention: LPs performed by left-handed physicians with patients in the right lateral recumbent position (RRP)
Number of subjects: 7200
Study 29912724 — intervention group
Group type: COMPARATOR
Intervention: LPs performed by left-handed physicians with patients in the left lateral recumbent position (LRP)
Number of subjects: 7200
Study 29912724 — intervention group
Group type: COMPARATOR
Intervention: LPs performed by right-handed physicians with patients in the right lateral recumbent position (RRP)
Number of subjects: 7200
Study 28745027 — intervention group
Group type: COMPARATOR
Intervention: β-TCP alone (Control group)
Number of subjects: 26
Study 28745027 — intervention group
Group type: EXPERIMENTAL
Intervention: P-PRP-mixed β-TCP (P-PRP group)
Number of subjects: 26
Study 28745027 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF-mixed β-TCP (PRF group)
Number of subjects: 26
Study 25879460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg OaD
Number of subjects: 423
Study 25879460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg PRN
Number of subjects: 423
Study 25879460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 23688060 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitted >5 years
Number of subjects: 3670
Study 23688060 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 3670
Study 21297656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified apical dissection technique (group 2)
Number of subjects: 42
Study 21297656 — intervention group
Group type: COMPARATOR
Intervention: Standard apical dissection technique (group 1)
Number of subjects: 42
Study 19223620 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-SP (sulfadoxine-pyrimethamine) administered at 3, 9, and 15 months of age
Number of subjects: 1200
Study 19223620 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTi-SP (sulfadoxine-pyrimethamine)
Number of subjects: 1200
Study 19223620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 16712936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 1.5 ppm
Number of subjects: 46
Study 16712936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 10 ppm
Number of subjects: 46
Study 16712936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-ethylhexanol at 20 ppm
Number of subjects: 46
Study 16712936 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable concentrations of 2-ethylhexanol over 4 hours
Number of subjects: 46
Study 16712936 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant concentrations of 2-ethylhexanol
Number of subjects: 46
Study 15031611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg (E20)
Number of subjects: 703
Study 15031611 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (L10)
Number of subjects: 703
Study 15031611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 703
Study 15031611 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (E20, L10, P)
Number of subjects: 703
Study 11180494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with placebo
Number of subjects: 10
Study 11180494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy combined with melatonin
Number of subjects: 10
Study 11180494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9663225 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC) during primary glaucoma triple procedure
Number of subjects: 174
Study 9663225 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive subconjunctival mitomycin C (MMC) for 3 minutes
Number of subjects: 174
Study 9663225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjunctive mitomycin C)
Number of subjects: 174
Study 7829176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen, administered 6 times at 15 minute intervals 90 minutes preoperatively in addition to the routine dilation regimen.
Number of subjects: 60
Study 7829176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flurbiprofen treatment).
Number of subjects: 60
Study 3278412 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (1,000 mg/day i.v. once daily for 14 days)
Number of subjects: 272
Study 3278412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 272
Study 31230026 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised training courses (weekly gym training and Taiji sessions), followed by a free 6-month unsupervised use of exercise facilities, and unsupervised low-cost exercise for another 12 months
Number of subjects: 914
Study 31230026 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 914
Study 29151036 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy (losartan 50-100 mg plus hydrochlorothiazide 12.5-25 mg)
Number of subjects: 605
Study 29151036 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy (losartan 50-100 mg or hydrochlorothiazide 12.5-25 mg)
Number of subjects: 605
Study 29151036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg) in phase 2
Number of subjects: 605
Study 29151036 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine with or without doxazosin in phase 3
Number of subjects: 605
Study 25591555 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 210
Study 23166203 — intervention group
Group type: COMPARATOR
Intervention: Combined-exercise training
Number of subjects: 40
Study 23166203 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 40
Study 23166203 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 40
Study 21604900 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-session short-term dynamic psychotherapy
Number of subjects: 50
Study 21604900 — intervention group
Group type: COMPARATOR
Intervention: 40-session cognitive treatment
Number of subjects: 50
Study 18836622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 134
Study 18836622 — intervention group
Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 134
Study 16441968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar dissection
Number of subjects: 245
Study 16441968 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection
Number of subjects: 245
Study 12544441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% alcohol beer
Number of subjects: 16
Study 12544441 — intervention group
Group type: COMPARATOR
Intervention: Usual alcohol intake
Number of subjects: 16
Study 11685784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed guidelines plus educational outreach visits from community pharmacists
Number of subjects: 20
Study 11685784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed guidelines only
Number of subjects: 20
Study 11685784 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11685784 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits
Number of subjects: 20
Study 9713471 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP‐MS containing 200 mg of cisplatin (n = 5)
Number of subjects: 15
Study 9713471 — intervention group
Group type: COMPARATOR
Intervention: CDDP‐S containing 100 mg of cisplatin (n = 10)
Number of subjects: 15
Study 9713471 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP‐MS
Number of subjects: 15
Study 8148215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 600 mg single dose followed by 300 mg thrice daily for 3 weeks
Number of subjects: 43
Study 8148215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) 300 mg thrice daily for 3 weeks
Number of subjects: 43
Study 8148215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8148215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 43
Study 8148215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) as add-on therapy
Number of subjects: 43
Study 2454440 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (morphine or equivalent doses)
Number of subjects: 0
Study 2454440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30529378 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal implants (placed approximately 2 mm below the bone crest)
Number of subjects: 128
Study 30529378 — intervention group
Group type: COMPARATOR
Intervention: Subcrestal implants (placed at bone crest level)
Number of subjects: 128
Study 30529378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 128
Study 28279602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymotrypsin combined with gentamicin via interventional sialendoscopy
Number of subjects: 104
Study 28279602 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 104
Study 26814466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite (SH1)
Number of subjects: 64
Study 26814466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (SH2)
Number of subjects: 64
Study 26814466 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Ricinus communis (RC)
Number of subjects: 64
Study 26814466 — intervention group
Group type: COMPARATOR
Intervention: 0.85% saline (C)
Number of subjects: 64
Study 22925498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-9 group (4 weekly instillations of 40 mg followed by 5 monthly instillations)
Number of subjects: 60
Study 22925498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-12 group (12 instillations of 40 mg every 2 weeks)
Number of subjects: 60
Study 22925498 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 21107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-load exercise test at 50% delta (Δ)
Number of subjects: 20
Study 21107600 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-load exercise test at 70% delta (Δ)
Number of subjects: 20
Study 21107600 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE regressed against proportion of time
Number of subjects: 20
Study 19933888 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated auditory hallucinations experience
Number of subjects: 150
Study 19933888 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (50 students)
Number of subjects: 150
Study 16506061 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 10
Study 16506061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 mg)
Number of subjects: 10
Study 15585783 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-chain fructooligosaccharides (10 g/d)
Number of subjects: 200
Study 15585783 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oligosaccharides (10 g/d)
Number of subjects: 200
Study 15585783 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides (10 g/d)
Number of subjects: 200
Study 15585783 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III resistant starch (10 g/d)
Number of subjects: 200
Study 15585783 — intervention group
Group type: EXPERIMENTAL
Intervention: NDCHs (2.5, 5.0, 7.5, or 10 g/d)
Number of subjects: 200
Study 15585783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 11760223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir suspension (1250 mg in 100 mL of water)
Number of subjects: 12
Study 11760223 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir tablets (five 250-mg tablets)
Number of subjects: 12
Study 11760223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir suspension
Number of subjects: 12
Study 9088601 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-mm elliptical extra broad light guide
Number of subjects: 30
Study 9088601 — intervention group
Group type: COMPARATOR
Intervention: 11-mm standard light guide
Number of subjects: 30
Study 8463441 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 18
Study 8463441 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 18
Study 8463441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3811814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (30 mg i.v. bolus followed by 1 mg/min for 8 hours)
Number of subjects: 40
Study 3811814 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 30209589 — intervention group
Group type: EXPERIMENTAL
Intervention: GM.CD40L
Number of subjects: 65
Study 30209589 — intervention group
Group type: COMPARATOR
Intervention: GM.CD40L.CCL21
Number of subjects: 65
Study 26846333 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (1.5 to 2.0 mg/kg)
Number of subjects: 144
Study 26846333 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 144
Study 26846333 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (2.0 mg/kg)
Number of subjects: 144
Study 26846333 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 144
Study 23160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-holders
Number of subjects: 0
Study 23160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinates
Number of subjects: 0
Study 23160813 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrals
Number of subjects: 0
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical workload at baseline
Number of subjects: 385
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical workload
Number of subjects: 385
Study 22539656 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 385